ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer

While ER has multiple biological effects, ER-cyclin D1-CDK4/6-RB is a critical pathway for the action of estrogen on the cell cycle, especially for breast cancers that rely on estrogen for growth. The latest and most efficient CDK4/6 inhibitors target the phosphorylation of retinoblastoma (RB) tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrossian, Karineh, Kanaya, Noriko, Lo, Chiao, Hsu, Pei-Yin, Nguyen, Duc, Yang, Lixin, Yang, Lu, Warden, Charles, Wu, Xiwei, Pillai, Raju, Bernal, Lauren, Huang, Chiun-Sheng, Kruper, Laura, Yuan, Yuan, Somlo, George, Mortimer, Joanne, Chen, Shiuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021239/
https://www.ncbi.nlm.nih.gov/pubmed/29963233
http://dx.doi.org/10.18632/oncotarget.25552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021239/
https://www.ncbi.nlm.nih.gov/pubmed/29963233
http://dx.doi.org/10.18632/oncotarget.25552

Ejemplares similares